Back

DPD quantification correlates with ECV and disease severity in patients with ATTR-CM

31 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: how to stage and score Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction
Doctor M. Llevadot Sesmilo (Badalona, ES)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of right ventricular dysfunction in patients with TTR amyloidosis
Doctor S. Istratoaie (Cluj Napoca, RO) Professor E. Donal (Rennes, FR)
Abstract Slides Video
Presentation thumbnail
Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms
Doctor E. Oikonomou (New Haven, US)
Abstract Slides Video
Presentation thumbnail
Prognostic staging system correctly identifies high risk groups in cardiac transthyretin amyloidosis treated with tafamidis
Mr M. Mueller (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Improving early mortality risk detection in light-chain cardiac amyloidosis patients with routine echocardiographic indicators and mayo staging
Doctor J. Li (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: how to stage and score

The Event

Event poster

ESC Congress 2024

31 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
DPD quantification correlates with ECV and disease severity in transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis
thumbnail
Congress Session
Evolving landscape in transthyretin amyloid cardiomyopathy (ATTR-CM): clinical practice and emerging treatments

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources